On December 5, 2017, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay over $27 million in damages to a patient injured by the companies’ most lucrative medication, Xarelto®. In a verdict that marks the first patient victory in the ongoing Xarelto® litigation, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay $27.8 million…
In November, 2015, the U.S. District Court for the Eastern District of Louisiana announced that the first of the Xarelto® bellwether trials, stemming from the Xarelto® multidistrict litigation, would begin in February, 2017. Since that announcement, there have been many updates in the ongoing legal battle against Xarelto® manufacturer Bayer AG and distributer Janssen Pharmaceuticals. Background Information In July of…
The FDA approved Zofran, an antiemetic medication manufactured by GlaxoSmithKline (GSK) to prevent nausea and vomiting caused by cancer chemo therapy, radiation therapy, and surgery. Although Zofran was approved for distribution only for chemotherapy and radiation patients, GSK promoted the drug as an effective means to fight the same symptoms in pregnant women. Over the past 20 years, doctors have…
Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. Consumer brand PPIs include Nexium, Prevacid and Prilosec. Yet, a recent study, which includes data from nearly 200,000 patients treated through the Department of Veterans Affairs, suggests a roughly…
Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. The medication works by obstructing the proton pump—an integral membrane protein—which then restricts or blocks the release of acid into a patient’s stomach. Common PPI medications include Prilosec, Nexium,…
In May, the United States Food and Drug Administration released information advising physicians and patients to be cautious about the risks related to SGLT2 inhibitors. Now, the FDA has updated the warning label for the drugs to include the risk of ketoacidosis and severe urinary tract infection. SGLT2 inhibitors, like the drug Invokana, work to improve glycemic control in patients…
Dates have been selected for the first Xarelto multidistrict litigation hearings. Pretrial discovery and bellwether trial selection for the Xarelto multidistrict litigation (MDL) has begun. The first trials will consist of a selection of four cases, from a pool of forty, that have been considered to represent the majority of the cases filed around the nation. The first of the…
In September, the Food and Drug Administration (FDA) strengthened a warning that linked diabetes drug Invokana to an increased risk of bone fractures. The warning came as the result of various separate clinical studies showing that the medication reduced bone density in patients, and caused severe fractures. The FDA will continue to monitor Invokana and other SLGT2 inhibitors for adverse…